BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bavituximab: Additional Phase II data

Additional data from a single-arm, 2-stage, open-label, Georgian Phase II trial in 46 patients with locally advanced or metastatic breast cancer showed that IV bavituximab plus docetaxel led to a median OS of 20.7 months. The company said data from a published study...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >